Related Experiment Video
Updated: Jul 31, 2026
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
Published on: June 22, 2012
Diagnostic approach to microangiopathic hemolytic disorders
1Medical Director Hemostasis and Thrombosis Robert J, Tomsich Pathology and Laboratory Medicine Institute Cleveland Clinic, 9500 Euclid Avenue, LL3-1 Cleveland, OH 44195.
Abstract:
Thrombotic micro-angiopathies (TMA) are a group of related disorders that are characterized by thrombosis of the microvasculature and associated organ dysfunction, and encompass congenital, acquired, and infectious etiologies. A hall mark of TMAs is the fragmentation of erythrocytes by the microvascular thrombi, resulting in a hemolytic anemia. There are several distinct pathophysiologies leading to microangiopathic hemolysis, ranging from decreased degradation of von Willebrand factor as seen in thrombotic thrombocytopenic purpura (TTP) to endothelial damage facilitated by Escherichia coli shiga toxin or complement dysregulation, seen in shiga toxin-related hemolytic-uremic syndrome (Stx-HUS) and complement-mediated TMA (also called atypical hemolytic-uremic syndrome), respectively. Distinguishing these disorders is important, as many TMAs are life-threatening, the treatments are distinct and selecting appropriate therapy can improve patient prognosis. Laboratory testing, including measurement of ADAMTS13, ADAMTS13 inhibitor, shiga toxin, and complement factors, can help establish diagnoses and guide therapy.
Insights
Thrombotic micro-angiopathies (TMA) involve microvascular thrombosis and organ damage. Laboratory tests help differentiate TMAs like TTP and HUS for targeted, life-saving treatments.
Area of Science:
- Hematology
- Nephrology
- Pathology
Background:
- Thrombotic micro-angiopathies (TMAs) are a spectrum of disorders characterized by microvascular thrombosis and organ dysfunction.
- Hallmarks include microangiopathic hemolytic anemia due to erythrocyte fragmentation.
Purpose of the Study:
- To highlight the importance of distinguishing between different TMA subtypes.
- To emphasize how accurate diagnosis guides distinct and potentially life-saving therapeutic strategies.
Main Methods:
- Review of distinct pathophysiologies leading to microangiopathic hemolysis.
- Discussion of laboratory tests for TMA diagnosis: ADAMTS13 activity, ADAMTS13 inhibitor levels, shiga toxin assays, and complement factor analysis.
Main Results:
- TMAs encompass diverse etiologies including decreased von Willebrand factor degradation (e.g., thrombotic thrombocytopenic purpura), endothelial damage from Escherichia coli shiga toxin (shiga toxin-related hemolytic-uremic syndrome), and complement dysregulation (complement-mediated TMA/atypical hemolytic-uremic syndrome).
- Laboratory testing aids in differentiating these conditions.
Conclusions:
- Accurate diagnosis of TMAs is critical due to their life-threatening nature and distinct treatment requirements.
- Appropriate therapeutic selection based on laboratory findings can significantly improve patient prognosis.
